Inclusion body myositis (IBM) is a rare, progressive inflammatory muscle disorder characterized by muscle weakness and degeneration. Current treatment products include immunoglobulin therapies, corticosteroids, and emerging monoclonal antibodies, each designed to modulate the immune response and slow disease progression. Advantages of these therapies lie in targeted immunomodulation, improved patient mobility, and a reduction in inflammatory markers, offering symptomatic relief in early and mid-stages of the disease.

Inclusion Body Myositis Market is a critical need for novel products due to limited efficacy of existing options, high unmet medical needs, and the condition’s refractory nature. Biologic agents under development aim to address underlying pathophysiology by targeting specific inflammatory pathways, thereby expanding treatment choices and improving quality of life. As diagnostic awareness grows, demand for advanced therapeutics intensifies, underpinning market opportunities and shaping future market trends.

The inclusion body myositis market is estimated to be valued at USD 557.6 Mn in 2025 and is expected to reach USD 822.0 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.7% from 2025 to 2032.

Get more insights on: Inclusion Body Myositis Market

Get this Report in JapaneseLanguage: 封入体筋炎市場

Get this Report in Korean Language: 포함체근염시장